norfloxacin has been researched along with cefaclor anhydrous in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guo, H | 1 |
| Bischoff, W; Hyslop, DL | 1 |
| Bischoff, W; Iravani, A | 1 |
| Deguchi, K; Fukayama, S; Ishihara, R; Koguchi, M; Nakane, Y; Oda, S; Sato, K; Suzuki, Y; Tanaka, S; Yokota, N | 1 |
| Claeys, G; Van den Abeele, AM; Verschraegen, G | 1 |
| Esko, E; Renkonen, OV | 1 |
| Andrews, JM; Brenwald, N; Wise, R | 1 |
| Deguchi, K; Ishihara, R; Ishii, Y; Nakazawa, A; Suzuki, Y | 1 |
| Gregory, WT; Guran, LA; McDonagh, MS; Price, JR | 1 |
4 review(s) available for norfloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Isatin derivatives and their anti-bacterial activities.
Topics: Anti-Bacterial Agents; Bacteria; Humans; Isatin; Structure-Activity Relationship | 2019 |
Antibiotic therapy for urinary tract infections.
Topics: Cefaclor; Cephalosporins; Clinical Trials as Topic; Europe; Female; Humans; Male; Norfloxacin; United States; Urinary Tract Infections | 1992 |
Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Cefaclor; Estriol; Female; Humans; Nitrofurantoin; Norfloxacin; Recurrence; Secondary Prevention; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2016 |
1 trial(s) available for norfloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefaclor; Cephalosporins; Diarrhea; Double-Blind Method; Europe; Female; Headache; Humans; Male; Middle Aged; Nausea; Norfloxacin; Pyelonephritis; Treatment Outcome; United States | 1992 |
8 other study(ies) available for norfloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Antibacterial activity of ciprofloxacin against fresh clinical isolates from superficial suppurative foci].
Topics: Amoxicillin; Bacteria; Cefaclor; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Suppuration | 1991 |
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Cefaclor; Ceftazidime; Cefuroxime; Ciprofloxacin; Clavulanic Acids; Corynebacterium; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Norfloxacin; Pefloxacin; Piperacillin; Staphylococcus; Vancomycin | 1988 |
Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cefaclor; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Penicillins; Staphylococcal Infections; Staphylococcus; Streptococcal Infections; Streptococcus; Urinary Tract Infections | 1985 |
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
Topics: Amoxicillin; Anti-Infective Agents; Bacteroides fragilis; Cefaclor; Chlamydia trachomatis; Chlamydophila pneumoniae; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Norfloxacin; Piperazines; Protein Binding; Quinolones; Staphylococcus | 1993 |
[The drug susceptibility pattern of the presumed etiologic agents of infectious enteritis including verotoxin-producing Escherichia coli O-157].
Topics: Aerobiosis; Ampicillin; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Campylobacter jejuni; Cefaclor; Cephalosporins; Chloramphenicol; Drug Resistance, Microbial; Enteritis; Escherichia coli O157; Fosfomycin; Humans; Microbial Sensitivity Tests; Minocycline; Norfloxacin; Penicillins; Salmonella; Tetracycline; Vibrio parahaemolyticus | 1997 |